Search results
Find Bristol Myers Squibb's annual reports, Form 10-Ks and annual reviews here.
- Investor relations - Bristol Myers Squibb
Find information and tools for investors, stockholders and...
- Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial ...
Bristol Myers Squibb posted fourth quarter revenues of $11.1...
- Investor relations - Bristol Myers Squibb
It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb...
1 day ago · Friday, Bristol Myers Squibb & Co (NYSE:BMY) posted second-quarter revenues of $12.20 billion, beating the consensus of $11.55 billion, an increase of 9% year-over-year, or 11% when adjusted for ...
Find information and tools for investors, stockholders and financial analysts, including share and dividend information, acquisition-related information, latest news and corporate reporting.
Feb 4, 2021 · Bristol Myers Squibb posted fourth quarter revenues of $11.1 billion, an increase of 39% on a reported basis and 10% on a pro forma basis. The increase was driven primarily by the impact of the Celgene Acquisition, which was completed on November 20, 2019. U.S. revenues increased 43% to $6.8 billion in the quarter.
This Annual Report also contains certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com .
can be found on our website at bms.com. See, “Quarterly package of financial Information” available on bms.com/investors for information on the list of specified items excluded from Non-GAAP EPS. 3 Portfolio achievements from 2H 2019-2022. 4 Includes $4.6 billion for dividends paid and $8.0 billion for common stock repurchases. early-stage ...
